Clinical and biological significance of RAS mutations in multiple myeloma
Open Access
- 5 June 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 22 (12), 2280-2284
- https://doi.org/10.1038/leu.2008.142
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Genetic events in the pathogenesis of multiple myelomaBest Practice & Research Clinical Haematology, 2007
- Clinical significance of TP53 mutation in myelomaLeukemia, 2007
- Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumorsPublished by American Society of Hematology ,2005
- Clinical and biologic implications of recurrent genomic aberrations in myelomaBlood, 2003
- Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentationBlood, 2001
- High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosisHuman Mutation, 2001
- The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myelomaCancer, 1999
- The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.1999
- Is Flow Cytometric DNA Content Hypodiploidy Prognostic in Multiple Myeloma?Leukemia & Lymphoma, 1999